DVA vs. LH, DGX, CHE, RCM, CRVL, AMED, AMN, MD, CCRN, and FMS
Should you be buying DaVita stock or one of its competitors? The main competitors of DaVita include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Chemed (CHE), R1 RCM (RCM), CorVel (CRVL), Amedisys (AMED), AMN Healthcare Services (AMN), Pediatrix Medical Group (MD), Cross Country Healthcare (CCRN), and Fresenius Medical Care (FMS).
Laboratory Co. of America (NYSE:LH) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.
In the previous week, Laboratory Co. of America had 3 more articles in the media than DaVita. MarketBeat recorded 11 mentions for Laboratory Co. of America and 8 mentions for DaVita. Laboratory Co. of America's average media sentiment score of 1.00 beat DaVita's score of 0.45 indicating that DaVita is being referred to more favorably in the news media.
DaVita has lower revenue, but higher earnings than Laboratory Co. of America. DaVita is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.
Laboratory Co. of America has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, DaVita has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.
95.9% of Laboratory Co. of America shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 0.9% of Laboratory Co. of America shares are owned by company insiders. Comparatively, 2.0% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Laboratory Co. of America received 108 more outperform votes than DaVita when rated by MarketBeat users. Likewise, 64.18% of users gave Laboratory Co. of America an outperform vote while only 61.75% of users gave DaVita an outperform vote.
DaVita has a net margin of 6.61% compared to DaVita's net margin of 3.52%. Laboratory Co. of America's return on equity of 68.52% beat DaVita's return on equity.
Laboratory Co. of America currently has a consensus target price of $241.86, indicating a potential upside of 24.09%. DaVita has a consensus target price of $144.67, indicating a potential downside of 1.67%. Given DaVita's stronger consensus rating and higher possible upside, analysts clearly believe Laboratory Co. of America is more favorable than DaVita.
Summary
Laboratory Co. of America beats DaVita on 11 of the 18 factors compared between the two stocks.
Get DaVita News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
